Vir Biotechnology, Inc. Stock News

Vir Biotechnology Inc has faced a tough year so far, with shares declining by 54% year-to-date. Much of the company's underperformance is attributed to unimpressive results from both influenza A and h

Vir Biotechnology's coronavirus treatment is losing steam. The company's pipeline looks somewhat promising on first glance.

Vir Biotechnology, Inc. (NASDAQ:VIR ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Sasha Damouni Ellis - EVP and Chief Corporate Affairs Officer Marianne De Backer -

Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $1.45 per share versus the Zacks Consensus Estimate of a loss of $1.21. This compares to loss of $0.58 per share a year ago.

Vir Biotechnology (VIR) crashes after the phase II study evaluating VIR-2482 for preventing symptomatic influenza A illness fails to meet goals.

Vir Biotechnology's shares plunged 45% to a more than three-year low on Thursday after the company's experimental antibody therapy to prevent a type of flu failed to meet its goals in a mid-stage tria

Vir Biotechnology has seen declining revenue because sales of its one marketed product, Sotrovimab, are declining. A phase 2 trial for an influenza A therapy didn't meet primary or secondary endpoints

Vir Biotechnology Inc. VIR, +0.92% said Thursday a mid-stage trial of a treatment for symptomatic flu failed to meet its main goals. The Phase 2 trial dubbed Peninsula was evaluating VIR-2482 for the

SAN FRANCISCO, June 05, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate

Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $1.06 per share versus the Zacks Consensus Estimate of a loss of $0.81. This compares to earnings of $3.85 per share a year ago.

While it might be difficult to navigate the equities sector now amid various headwinds, biotech stocks to buy may offer a surprising respite. True, the market presence of the surprise production cuts

Investors need to pay close attention to Vir Biotechnology (VIR) stock based on the movements in the options market lately.

SAN FRANCISCO, March 08, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Executive Vice President, Chief Medical Officer and Interim Head of

Biotech stocks almost always have the potential for significant growth over time. Companies in the sector operate in areas including drug development, medical devices, and diagnostics.

Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of -1,800% and 80.07%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the st